UA31885U - 6-аминоэтил-6н-индоло-[2,3-b]хиноксалины как противовирусные агенты и индукторы интерферонов - Google Patents
6-аминоэтил-6н-индоло-[2,3-b]хиноксалины как противовирусные агенты и индукторы интерферонов Download PDFInfo
- Publication number
- UA31885U UA31885U UAU200714028U UAU200714028U UA31885U UA 31885 U UA31885 U UA 31885U UA U200714028 U UAU200714028 U UA U200714028U UA U200714028 U UAU200714028 U UA U200714028U UA 31885 U UA31885 U UA 31885U
- Authority
- UA
- Ukraine
- Prior art keywords
- ppm
- indolo
- mol
- interferon
- benzene
- Prior art date
Links
- 239000003443 antiviral agent Substances 0.000 title claims abstract description 8
- 239000002799 interferon inducing agent Substances 0.000 title abstract description 10
- GDNBIYLDDMJRCC-UHFFFAOYSA-N 2-indolo[3,2-b]quinoxalin-6-ylethanamine Chemical class C1=CC=C2N=C3N(CCN)C4=CC=CC=C4C3=NC2=C1 GDNBIYLDDMJRCC-UHFFFAOYSA-N 0.000 title abstract 2
- 102000014150 Interferons Human genes 0.000 claims description 15
- 108010050904 Interferons Proteins 0.000 claims description 15
- 239000000411 inducer Substances 0.000 claims description 3
- 229940047124 interferons Drugs 0.000 claims description 2
- DSYFNRZHDYNTTD-UHFFFAOYSA-N 2-quinoxalin-2-ylquinoxaline Chemical class C1=CC=CC2=NC(C3=NC4=CC=CC=C4N=C3)=CN=C21 DSYFNRZHDYNTTD-UHFFFAOYSA-N 0.000 claims 1
- 238000012876 topography Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 20
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 20
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 14
- 125000001931 aliphatic group Chemical group 0.000 description 14
- 125000003118 aryl group Chemical group 0.000 description 14
- 238000001819 mass spectrum Methods 0.000 description 14
- 238000001228 spectrum Methods 0.000 description 14
- CYLJJGWXJNNBDU-UHFFFAOYSA-N 2-[2,3-bis(2-aminoethyl)phenyl]ethanamine Chemical compound NCCC1=CC=CC(CCN)=C1CCN CYLJJGWXJNNBDU-UHFFFAOYSA-N 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 13
- OAIVIYSBZFEOIU-UHFFFAOYSA-N chloroform;propan-2-one Chemical compound CC(C)=O.ClC(Cl)Cl OAIVIYSBZFEOIU-UHFFFAOYSA-N 0.000 description 13
- 229940079322 interferon Drugs 0.000 description 13
- 238000004113 cell culture Methods 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 12
- 230000000120 cytopathologic effect Effects 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 230000000840 anti-viral effect Effects 0.000 description 10
- 241000700605 Viruses Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000002356 single layer Substances 0.000 description 8
- 229960000583 acetic acid Drugs 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 241000711975 Vesicular stomatitis virus Species 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- 239000012362 glacial acetic acid Substances 0.000 description 4
- JXDYKVIHCLTXOP-UHFFFAOYSA-N isatin Chemical compound C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- LJHHJFAUMZLYRE-UHFFFAOYSA-N 2-(2,3-dimethylindolo[3,2-b]quinoxalin-6-yl)ethyl-dimethylazanium;chloride Chemical compound Cl.CC1=C(C)C=C2N=C3N(CCN(C)C)C4=CC=CC=C4C3=NC2=C1 LJHHJFAUMZLYRE-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 229940126601 medicinal product Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- APQIUTYORBAGEZ-UHFFFAOYSA-N 1,1-dibromoethane Chemical compound CC(Br)Br APQIUTYORBAGEZ-UHFFFAOYSA-N 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
- SJALPCXFOSGNST-UHFFFAOYSA-N 1-(2-bromoethyl)indole-2,3-dione Chemical compound C1=CC=C2N(CCBr)C(=O)C(=O)C2=C1 SJALPCXFOSGNST-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- QCOGKXLOEWLIDC-UHFFFAOYSA-N N-methylbutylamine Chemical compound CCCCNC QCOGKXLOEWLIDC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000006286 aqueous extract Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- -1 2-(4-Methyl-piperazin-1-yl)-ethyl Chemical group 0.000 description 1
- NNWUEBIEOFQMSS-UHFFFAOYSA-N 2-Methylpiperidine Chemical compound CC1CCCCN1 NNWUEBIEOFQMSS-UHFFFAOYSA-N 0.000 description 1
- UZOFELREXGAFOI-UHFFFAOYSA-N 4-methylpiperidine Chemical compound CC1CCNCC1 UZOFELREXGAFOI-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 101000939500 Homo sapiens UBX domain-containing protein 11 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 102100029645 UBX domain-containing protein 11 Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- UOMKBIIXHQIERR-UHFFFAOYSA-N cridanimod Chemical compound C1=CC=C2N(CC(=O)O)C3=CC=CC=C3C(=O)C2=C1 UOMKBIIXHQIERR-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- WEHWNAOGRSTTBQ-UHFFFAOYSA-N dipropylamine Chemical compound CCCNCCC WEHWNAOGRSTTBQ-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000286 interferogenic effect Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- QHCCDDQKNUYGNC-UHFFFAOYSA-N n-ethylbutan-1-amine Chemical compound CCCCNCC QHCCDDQKNUYGNC-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000004651 near-field scanning optical microscopy Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAU200714028U UA31885U (ru) | 2007-12-13 | 2007-12-13 | 6-аминоэтил-6н-индоло-[2,3-b]хиноксалины как противовирусные агенты и индукторы интерферонов |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAU200714028U UA31885U (ru) | 2007-12-13 | 2007-12-13 | 6-аминоэтил-6н-индоло-[2,3-b]хиноксалины как противовирусные агенты и индукторы интерферонов |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA31885U true UA31885U (ru) | 2008-04-25 |
Family
ID=39819926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAU200714028U UA31885U (ru) | 2007-12-13 | 2007-12-13 | 6-аминоэтил-6н-индоло-[2,3-b]хиноксалины как противовирусные агенты и индукторы интерферонов |
Country Status (1)
| Country | Link |
|---|---|
| UA (1) | UA31885U (ru) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2445094C1 (ru) * | 2010-10-05 | 2012-03-20 | Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" | Интерферониндуцирующее средство для лечения острых респираторных вирусных инфекций (орви) |
-
2007
- 2007-12-13 UA UAU200714028U patent/UA31885U/ru unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2445094C1 (ru) * | 2010-10-05 | 2012-03-20 | Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" | Интерферониндуцирующее средство для лечения острых респираторных вирусных инфекций (орви) |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Meyer et al. | In vitro evaluation of phosphocholine and quaternary ammonium containing lipids as novel anti-HIV agents | |
| SU1528316A3 (ru) | Способ получени производных дистамицина А или их гидрохлоридов | |
| US4268672A (en) | Adenosine deaminase resistant antiviral purine nucleosides and method of preparation | |
| CS251060B2 (en) | 9-(hydroxyalkyl)purines' derivatives salts production method | |
| CN105640951B (zh) | 不对称芳香二硫醚类化合物作为病毒3c蛋白酶抑制剂在制备抗病毒药物中的应用 | |
| UA31885U (ru) | 6-аминоэтил-6н-индоло-[2,3-b]хиноксалины как противовирусные агенты и индукторы интерферонов | |
| CN118076589A (zh) | 一种酰胺类化合物、其制备方法和制药用途 | |
| RU2404987C2 (ru) | Антинеоплазические соединения и фармацевтические композиции на их основе | |
| US10098899B2 (en) | Drug with activity against the herpes virus family | |
| CN108938657A (zh) | 黄芩苷和黄芩苷衍生物在制备治疗牛病毒性腹泻病药物中的应用及黄芩苷衍生物 | |
| CN104311442B (zh) | 卤代萘环的丁二酸酰胺衍生物、其制备方法及用途 | |
| PT87605B (pt) | Processo para a preparacao do isomero s de um derivado de purina | |
| WO1986000904A1 (en) | Etherified 2-hydroxy-ethyl-phosphonic acid derivatives and plant growth regulating agents containing same as active ingredient | |
| UA92174C2 (ru) | Аминоэтил-6н-индоло-[2,3-в]хиноксалины как противовирусные агенты по отношению к вирусу везикулярного стоматита и индукторы интерферонов | |
| CN112159395B (zh) | 4-丙胺酸取代胞嘧啶核苷类化合物及其药物用途 | |
| CN104292123B (zh) | 苯基萘环的丁二酸酰胺衍生物、其制备方法及用途 | |
| NO853063L (no) | Fremgangsmaate ved fremstilling av substituerte guanidinbenzosyrefenylestere. | |
| US4939156A (en) | New tetramethyl-cis-diaza-bicyclo{4.2.0}octane-3,5-dione derivatives having differentiation-inducing activity and antiviral activity | |
| CA1304359C (en) | Antitumor and antiviral compositions of marine origin | |
| RU2697716C1 (ru) | Гидрохлорид 1,7,7-триметилбицикло[2.2.1]гептан-2-ил 3-(пиперидин-1-ил)пропионат, используемый в качестве ингибитора вируса Эбола | |
| CN109232599B (zh) | 具有抗肿瘤活性的o-对三氟甲基苯甲酰基土甘草a及其制备方法和用途 | |
| UA89992C2 (ru) | ДИАЛКИЛАМИНОАЛКИБЕНЗИМИДАЗО[1,2-с]ХИНАЗОЛИНЫ КАК ПРОТИВОВИРУСНЫЕ АГЕНТЫ И ИНДУКТОРЫ ИНТЕРФЕРОНА | |
| CN104311445B (zh) | 含萘环的丁二酸酰胺衍生物、其制备方法及用途 | |
| UA18602U (en) | 6-[2-(diethylamino)ethyl]-6h-indolo-(2,3-b]quinoxalines as antiviral agents and inductors of interferon | |
| UA32159U (ru) | ДИАЛКИЛАМИНОАЛКИЛБЕНЗИМИДАЗО[1,2-с]ХИНАЗОЛИНЫ КАК ПРОТИВОВИРУСНЫЕ АГЕНТЫ И ИНДУКТОРЫ ИНТЕРФЕРОНА |